Increased Anterior Cingulate/Medial Prefrontal Cortical Glutamate and Creatine in Bipolar Depression

UCLA Department of Psychiatry and Biobehavioral Sciences, Los Angeles, CA 55905, USA.
Neuropsychopharmacology (Impact Factor: 7.83). 01/2008; 32(12):2490-9. DOI: 10.1038/sj.npp.1301387
Source: PubMed

ABSTRACT Proton magnetic resonance spectroscopy ((1)HMRS) is an in vivo brain imaging method that can be used to investigate psychotropic drug mechanism of action. This study evaluated baseline (1)HMRS spectra of bipolar depressed patients and whether the level of cerebral metabolites changed after an open trial of lamotrigine, an anti-glutamatergic mood stabilizer. Twenty-three bipolar depressed and 12 control subjects underwent a MRS scan of the anterior cingulate/medial prefrontal cortex. The scan was performed on a GE whole-body 1.5 T MRI scanner using single-voxel PRESS (TE/TR=30/3000 ms, 3 x 3 x 3 cm(3) and post-processed offline with LCModel. Baseline CSF-corrected absolute concentrations of glutamate+glutamine ([Glx]), glutamate ([Glu]), and creatine+phosphocreatine ([Cr]) were significantly higher in bipolar depressed subjects vs healthy controls. The non-melancholic subtype had significantly higher baseline [Glx] and [Glu] levels than the melancholic subtype. Remission with lamotrigine was associated with significantly lower post-treatment glutamine ([Gln]) in comparison to non-remission. These data suggest that non-melancholic bipolar depression is characterized by increased glutamate coupled with increased energy expenditure. Lamotrigine appears to reduce glutamine levels associated with treatment remission. Further study is encouraged to determine if these MR spectroscopic markers can delineate drug mechanism of action and subsequent treatment response.

Download full-text


Available from: Jim Mintz, Aug 05, 2014
  • Source
    • "In bipolar disorder, the 1 H MRS studies are also mixed, with evidence of increased frontal (Castillo et al., 2000; Frye et al., 2007; Ongür et al., 2008), increased occipital (Bhagwagar et al., 2007) and decreased frontal (Port et al., 2008) GLU (or GLX) levels while there have also been reports of null findings in frontal (Davanzo et al., 2003; Moore et al., 2007), hippocampal (Gigante et al., 2014; Zanetti et al., 2014) and occipital (Davanzo et al., 2003) regions. A recent review (Yuksel and Ongur, 2010) has suggested that GLU may distinguish depressive from manic episodes, with reduced levels found to be consistent with the former and increased levels consistent with the latter. "
    [Show abstract] [Hide abstract]
    ABSTRACT: While numerous studies have employed magnetic resonance spectroscopy (MRS) to determine in vivo neurometabolite levels associated with mood disorders the findings in both unipolar depression and bipolar disorder have been mixed. Data-driven studies may shed new light on this literature by identifying distinct subgroups of patients who may benefit from different treatment strategies. The objective of the present study was to utilize hierarchical cluster analysis in order to generate new hypotheses with respect to neurometabolic profiling of mood disorder. Participants were 165 young persons (18-30 yrs) with a mood disorder and 40 healthy controls. Neurometabolite levels were recorded via proton-MRS ((1)H MRS). The ratios (relative to creatine) of glutamate (GLU), N-acetyl aspartate (NAA) and myo-inositol (MI) measured within the hippocampus. Self-reported and clinician rated symptoms as well as cognition were also measured. The unipolar depression (N=90) and bipolar disorder (N=75) groups did not significantly differ (from each other or controls) in their levels of GLU, NAA or MI. Cluster analyses derived four subgroups of patients who were distinguished by all three metabolites. There was a pattern of positive association between NAA and GLU, whereby clusters were abnormally increased (clusters 1, 2) or normal (cluster 4) or abnormally decreased (cluster 3) in these neurometabolites. These findings suggest that there are neurometabolic abnormalities in subgroups of young people with mood disorder, which may occur despite diagnostic similarities. Such evidence highlights that the underlying neurobiology of mood disorder is complex and MRS may have unique utility in delineating underlying neurobiology and targeting treatment strategies. Copyright © 2015 Elsevier B.V. and ECNP. All rights reserved.
    European Neuropsychopharmacology 02/2015; 25(6). DOI:10.1016/j.euroneuro.2015.02.009 · 5.40 Impact Factor
  • Source
    • "Both cellular energy production processes – through the coupling between glucose consumption and Glu-Gln cycling (Ende et al., 2000; Dager et al., 2008) – and GSK3 activity (Du et al., 2010) may influence glutamatergic transmission. While it has been hypothesized that depressive and manic episodes may be characterized by modulation of the Gln/ Glu ratio in opposite directions and also that BD would be associated with an overall increase in brain Glu or Glx levels (Yüksel and Öngür, 2010), the studies supporting this view have mostly enrolled patients under mood stabilizer medication and/ or with a chronic course (> 10 years) of illness (Frye et al., 2007; Colla et al., 2009; Gigante et al., 2012). Moreover, as low-dose lithium has been shown to be as effective as standard dose therapy – but associated with a A c c e p t e d M a n u s c r i p t 15 lower incidence of side effects – for the treatment of bipolar depression (Kleindienst et al., 2005; Machado-Vieira et al., 2009, 2014), the present finding raises the possibility that the use of lithium dosages with plasma levels higher than 0.50mmol/L increases the risk of regional toxic effects in the hippocampus due to overexposure to high Glu levels (Machado- Vieira et al., 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hippocampus has been highly implicated in the pathophysiology of bipolar disorder (BD). Nevertheless, no study has longitudinally evaluated hippocampal metabolites levels in bipolar depression under treatment with lithium. Nineteen medication-free BD patients (78.9% treatment-naïve and 73.7% with BD type II) presenting an acute depressive episode and 17 healthy controls were studied. Patients were treated for 6 weeks with lithium in an open-label trial. N-acetyl aspartate (NAA), creatine, choline, myo-Inositol and glutamate levels were assessed in the left hippocampus before (week 0) and after lithium treatment (week 6) using 3T proton magnetic resonance spectroscopy (1H-MRS). The metabolite concentrations were estimated using internal water as reference and voxel segmentation for partial volume correction. At baseline, acutely depressed BD patients and healthy controls exhibited similar hippocampal metabolites concentrations, with no changes after 6 weeks of lithium monotherapy. A significant correlation between antidepressant efficacy and increases in NAA concentration over time was observed. Also, there was a significant positive correlation between the changes in glutamate concentrations over follow-up and plasma lithium levels at endpoint. Mixed effects model analysis revealed a bimodal effect of lithium plasma levels in hippocampal glutamate concentrations: levels of 0.2 to 0.49mmol/L (n=9) were associated with a decrease in glutamate concentrations, whereas the subgroup of BD subjects with "standard" lithium levels (= 0.50mmol/L) (n=10) showed an overall increase in glutamate concentrations over time. These preliminary results suggest that lithium has a bimodal action in hippocampal glutamate concentration depending on the plasma levels. Clinical trial number NCT01919892. © The Author 2014. Published by Oxford University Press on behalf of CINP.
    The International Journal of Neuropsychopharmacology 10/2014; 18(6). DOI:10.1093/ijnp/pyu058 · 5.26 Impact Factor
  • Source
    • "According to a study which distinguished the melancholic and non-melancholic subtypes of BD depression, Glx was more heightened in the BD group in comparison with the control group, and the increase in Glx was more pronounced in the melancholic BD subgroup [41]. In addition, after treatment with lamotrigine, an anti-glutamatergic mood stabilizer, the treatment group that had undergone remission showed a significant reduction in Glx, compared to the non-remission group [41]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The role of glutamatergic system in the neurobiology of mood disorders draws increasing attention, as disturbance of this system is consistently implicated in mood disorders including major depressive disorder and bipolar disorder. Thus, the glutamate hypothesis of mood disorders is expected to complement and improve the prevailing monoamine hypothesis, and may indicate novel therapeutic targets. Since the contribution of astrocytes is found to be crucial not only in the modulation of the glutamatergic system but also in the maintenance of brain energy metabolism, alterations in the astrocytic function and neuroenergetic environment are suggested as the potential neurobiological underpinnings of mood disorders. In the present review, the evidence of glutamatergic abnormalities in mood disorders based on postmortem and magnetic resonance spectroscopy (MRS) studies is presented, and disrupted energy metabolism involving astrocytic dysfunction is proposed as the underlying mechanism linking altered energy metabolism, perturbations in the glutamatergic system, and pathogenesis of mood disorders.
    03/2014; 23(1):28-35. DOI:10.5607/en.2014.23.1.28
Show more